UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission File Number: 001-38283

InflaRx N.V.
(Translation of registrant's name into English)

Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

EXPLANATORY NOTE

On June 21, 2023, InflaRx N.V. issued a press release titled “InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

2
EXHIBIT INDEX

Exhibit No.
Description

Press Release, dated June 21, 2023

3
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INFLARX N.V.


Date: June 21, 2023
By:
/s/ Niels Riedemann

Name:
Niels Riedemann

Title:
Chief Executive Officer


4
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more InflaRx NV Charts.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more InflaRx NV Charts.